Piper Sandler raises Doximity price target to $47, keeps Overweight rating
Piper Sandler’s Jessica Tassan reiterates an Overweight rating on Doximity (DOCS) and lifts the price target to $47 from $42. The move reflects sustained optimism about the company’s prospects, offering a clear upside indicator for shareholders.
*this image is generated using AI for illustrative purposes only.
Piper Sandler analyst Jessica Tassan has reiterated an Overweight rating on Doximity Inc. (NYSE: DOCS) and raised its price target from $42 to $47. The adjustment signals increased confidence in the company’s growth trajectory and market position within the healthcare technology sector. For investors holding or considering shares of Doximity, the higher price target suggests potential upside from current trading levels, reinforcing the firm’s bullish stance.
Analyst Action Details
The research note maintains the existing recommendation while adjusting the valuation metric. This is a common practice when analysts believe a stock’s fundamentals have strengthened or when broader market conditions favor the sector, even if the core investment thesis remains unchanged.
| Analyst | Firm | Rating | Previous PT | New PT |
|---|---|---|---|---|
| Jessica Tassan | Piper Sandler | Overweight | $42 | $47 |
Market Implications
The raise in the price target by $5 represents approximately a 11.9% increase in the firm’s expected fair value for Doximity. While the source document does not specify the underlying drivers for this change, such adjustments often follow positive earnings reports, new product launches, or favorable industry trends. Investors typically monitor these updates as signals of institutional sentiment.
What the Numbers Show
The consistent Overweight rating indicates that Piper Sandler views Doximity as undervalued relative to its peers or intrinsic worth. The upward revision in the price target narrows the gap between current market pricing and the analyst’s projected value, potentially attracting further institutional interest if the stock trades below the new $47 benchmark.
What specific recent developments in Doximity's product suite or user engagement metrics likely prompted Piper Sandler to raise its price target by nearly 12%?
How does Doximity's current valuation compare to other major players in the healthcare technology sector, and does the new $47 target still reflect a significant discount?
Could broader regulatory changes in healthcare data privacy or telehealth reimbursement policies impact Doximity's growth trajectory in the next fiscal year?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
